[Evaluation of influenza vaccine Vaxigrip in the combined immunization of conscripts during influenza seasons of 2002-2003].
The immunization properties of the influenza vaccine Vaxigrip, used in combination with vaccines against pneunococcal infection and hepatitis A (respectively, Pneumo 23 and Avaxim), were evaluated. In Central Russia in one of the units of the internal forces of the RF Ministry of Internal Affairs 3 groups totaling 755 servicemen were formed, depending on the complex of the introduced vaccines. Active medical observation and the registration of the complaints of the vaccinees at the postvaccinal period did not reveal unusual reactions and complications in none of the groups under observation. In the evaluation of the level of specific antibodies to the circulating influenza viruses prior to vaccination the low level of collective protection to influenza B virus was determined: protective antibody levels were registered only in 14-18% of the servicemen, while the corresponding data with respect of influenza viruses A(H1N1) and A(H3N2) were 45-50% and 56-63% respectively. At the same time, in seronegative persons the vaccine Vaxigrip exhibited high immunogenic activity with respect of all 3 influenza strains; seroconversion to them was determined in 84-92% of the vaccines, and the level of protective antibody titers before the beginning of the epidemic season was 86-99% in the whole of the group. The characteristics of the prophylactic effectiveness of the vaccine Vaxigrip in relation to the influenza virus infection level 1 were 4.7 (index) and 79% (coefficient). In addition, the frequency of influenza cases, clinically pronounced and confirmed by laboratory methods, in patients who had been immunized with 3 vaccines was 6.7%, which was 10.3 times less frequent than number of cases in the groups of comparison (68.2% on the average). The coefficient of epidemiological effectiveness of the prophylaxis of influenza was 90.2%. The complex use of 3 preparations did not affect the immunization properties of the vaccine Vaxigrip.
Burtseva
E I
EI
Ivanovsky Research Institute of Virology, Military Medical Command, Ministry of Internal Affairs, Moscow, Russia.
Vlasova
L N
LN
Shevchenko
E S
ES
Sabanin
Iu V
IuV
Rikhter
V V
VV
Artiukov
R M
RM
Rybin
V V
VV
Tarasevich
N N
NN
Slepushkin
A N
AN
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D006506:Hepatitis A / Q000276:immunology; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D029521:Alphainfluenzavirus / Q000276:immunology; D029524:Betainfluenzavirus / Q000276:immunology; D008297:Male; D008889:Military Personnel; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D012426:Russia; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000008:administration & dosage*; D014765:Viral Vaccines / Q000008:administration & dosage
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; C478242:vaxigrip